Anakinra improves exercise peak aerobic capacity in patients with recently decompensated systolic heart failure

• Published in: Vascular pharmacology Vol. 103-105; p. 47
• Main Authors: Van Tassell, B.W., Viscusi, M.M., Del Buono, M.G., Canada, J., Carbone, S., Trankle, C., Buckley, L., Lesnefsky, E., Arena, R., Abbate, A.
• Format: Journal Article
• Language: English
• Published: Philadelphia Elsevier Inc 01.04.2018; Elsevier Science Ltd
• Subjects: Aerobic capacity; C-reactive protein; Clinical trials; Drug therapy; Exercise; Heart diseases; Heart failure; Interleukin 1 receptor antagonist; Oxygen consumption; Patients; Proteins; Vanadium oxides

Objective: To evaluate the effects of anakinra on aerobic exercise capacity in patients with recently decompensated systolic HF and systemic inflammation. Methods: We randomly assigned 60 patients with reduced leftventricular ejection fraction (<50%) and elevated C-reactive protein (CRP) levels (...